Home › Modalities › Small Molecule
Small Molecule (142 companies)
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| AARD | Aardvark Therapeutics | DermatologyMetabolic+1 Rare | 2 | Phase 3 | $25.2M | 3 |
| ABVX | Abivax | Immunology | 2 | Phase 3 | $7.19B | 2 |
| ACIU | AC Immune | Neurology Rare | 6 | Phase 3 | $210M | 11 |
| QUIT | Achieve Life Sciences | — | 2 | NDA Submitted | $673M | 2 |
| ACRS | Aclaris Therapeutics | DermatologyGI/Hepatology+1 Rare | 4 | Phase 2 | $536M | 7 |
| ACRV | Acrivon Therapeutics | GI/HepatologyOncology Rare | 9 | Phase 2 | $61.4M | 9 |
| ACTU | Actuate Therapeutics | Oncology | 4 | Phase 2 | $15.2M | 4 |
| AGIO | Agios Pharmaceuticals | HematologyMetabolic Rare | 6 | Approved | $1.79B | 7 |
| AGMB | Agomab Therapeutics | ImmunologyRespiratory Rare | 2 | Phase 2 | $292M | 4 |
| AKBA | Akebia Therapeutics | HematologyOphthalmology+2 Rare | 7 | Approved | $111M | 10 |
| ALDX | Aldeyra Therapeutics | DermatologyOncology+1 | 5 | NDA Submitted | $41.9M | 5 |
| ATHE | Alterity Therapeutics | Neurology Rare | 2 | Phase 2 | $35.7M | 2 |
| ANRO | Alto Neuroscience | Neurology | 6 | Phase 2 | $999M | 6 |
| ALMS | Alumis | DermatologyImmunology+1 | 5 | Phase 3 | $628M | 5 |
| AMLX | Amylyx Pharmaceuticals | MetabolicNeurology Rare | 1 | Phase 3 | $3.54B | 5 |
| ANTX | AN2 Therapeutics | HematologyInfectious Disease+1 Rare | 6 | Phase 2 | $161M | 6 |
| ANNX | Annexon | HematologyNeurology+2 Rare | 1 | Phase 3 | $662M | 6 |
| RCUS | Arcus Biosciences | DermatologyImmunology+1 | 3 | Phase 3 | $2.36B | 8 |
| ARDX | Ardelyx | GI/HepatologyRenal | 4 | Approved | $799M | 4 |
| AVBP | ArriVent BioPharma | Oncology | 1 | Phase 3 | $553M | 7 |
| ARVN | Arvinas | NeurologyOncology Rare | 10 | Approved | $447M | 10 |
| ATAI | Atai Beckley | Neurology | 5 | Phase 2 | $2.73B | 5 |
| AXSM | Axsome Therapeutics | Neurology Rare | 15 | Approved | $7.15B | 15 |
| BLTE | Belite Bio | MetabolicOphthalmology Rare | 6 | NDA Submitted | $6.35B | 6 |
| BIOA | BioAge Labs | CardiovascularOphthalmology | 2 | Phase 2 | $234M | 2 |
| BCRX | Biocryst Pharmaceuticals | DermatologyImmunology+1 Rare | 2 | Approved | $1.93B | 4 |
| BMEA | Biomea Fusion | MetabolicOncology | 4 | Phase 2 | $35.5M | 4 |
| BDTX | Black Diamond Therapeutics | Oncology | 4 | Phase 2 | $82.8M | 4 |
| BBOT | BridgeBio Oncology Therapeutics | Oncology | 6 | Phase 1 | $156M | 6 |
| CCCC | C4 Therapeutics | Oncology | 2 | Phase 2 | $332M | 2 |
| CRDL | Cardiol Therapeutics | Cardiovascular Rare | 4 | Phase 3 | $124M | 4 |
| CRVO | CervoMed | Neurology Rare | 4 | Phase 2 | $22.7M | 4 |
| CING | Cingulate | Neurology | 1 | NDA Submitted | $70.6M | 1 |
| CLNN | Clene | Neurology Rare | 5 | NDA Submitted | $46.4M | 5 |
| CLYM | Climb Bio | HematologyImmunology+1 Rare | 1 | Phase 2 | $574M | 8 |
| COGT | Cogent Biosciences | HematologyOncology Rare | 6 | NDA Submitted | $4.85B | 7 |
| CGTX | Cognition Therapeutics | Neurology | 2 | Phase 2 | $59.9M | 2 |
| CMPS | COMPASS Pathways | Neurology | 3 | NDA Submitted | $1.13B | 3 |
| CTNM | Contineum Therapeutics | NeurologyRespiratory Rare | 4 | Phase 2 | $375M | 4 |
| CRVS | Corvus Pharmaceuticals | DermatologyOncology+1 Rare | 6 | Phase 3 | $858M | 7 |
| CRNX | Crinetics Pharmaceuticals | MetabolicOncology Rare | 6 | Approved | — | 6 |
| CGEM | Cullinan Therapeutics | HematologyImmunology+2 Rare | 1 | NDA Submitted | $602M | 10 |
| DFTX | Definium Therapeutics | Neurology | 4 | Phase 3 | $4.02B | 4 |
| IRON | Disc Medicine | GI/HepatologyHematology+2 Rare | 3 | Phase 3 | $3.49B | 9 |
| EWTX | Edgewise Therapeutics | Cardiovascular | 3 | Phase 2 | $4.60B | 3 |
| EIKN | Eikon Therapeutics | Oncology | 13 | Phase 2 | $279M | 13 |
| ELOX | Eloxx Pharmaceuticals | DermatologyRenal Rare | 4 | Phase 2 | $48.0M | 4 |
| ENTA | Enanta Pharmaceuticals | DermatologyImmunology+2 | 8 | Approved | $253M | 8 |
| ELVN | Enliven Therapeutics | Oncology | 1 | Phase 1 | $3.45B | 1 |
| ERAS | Erasca | Oncology | 4 | Phase 1 | $4.87B | 5 |
| ETON | Eton Pharmaceuticals | GI/HepatologyInfectious Disease+3 Rare | 13 | Approved | $1.84B | 17 |
| EVMN | Evommune | DermatologyImmunology+1 | 4 | Phase 2 | $290M | 6 |
| EXEL | Exelixis | CardiovascularOncology | 17 | Approved | $16.7B | 23 |
| EYPT | EyePoint | Ophthalmology | 2 | Phase 3 | $34.1M | 2 |
| FHTX | Foghorn Therapeutics | Oncology | 1 | Preclinical | $110M | 4 |
| FBIO | Fortress Biotech | DermatologyHematology+4 Rare | 9 | Approved | $61.4M | 16 |
| GANX | Gain Therapeutics | MetabolicNeurology Rare | 4 | Phase 1 | $52.5M | 5 |
| GHRS | GH Research | NeurologyWomen's Health | 4 | Phase 2 | $1.25B | 4 |
| GOSS | Gossamer Bio | Cardiovascular Rare | 4 | NDA Submitted | $67.5M | 4 |
| GRCE | Grace Therapeutics | Neurology | 1 | NDA Submitted | $36.2M | 1 |
| HRMY | Harmony Biosciences | MetabolicNeurology Rare | 14 | Approved | $1.94B | 17 |
| HROW | Harrow | Ophthalmology Rare | 11 | Approved | $1.11B | 15 |
| HELP | Helus Pharma | Neurology | 3 | Phase 3 | $575M | 3 |
| IDYA | IDEAYA Biosciences | Oncology | 11 | NDA Submitted | $2.65B | 15 |
| IMRX | Immuneering | Oncology | 5 | Phase 3 | $224M | 5 |
| IMUX | Immunic | GI/HepatologyNeurology | 4 | Phase 3 | $116M | 4 |
| IBRX | ImmunityBio | Infectious DiseaseOncology | 1 | Approved | $6.66B | 17 |
| IMNM | Immunome | Oncology Rare | 1 | NDA Submitted | $2.03B | 9 |
| IXHL | Incannex Healthcare | NeurologyRespiratory | 2 | Phase 2 | $21.8M | 2 |
| INSM | Insmed | CardiovascularImmunology+3 Rare | 9 | Approved | $26.7B | 15 |
| KAPA | Kairos Pharma | Oncology | 3 | Phase 2 | $1.9M | 12 |
| KZIA | Kazia Therapeutics | NeurologyOncology Rare | 9 | Phase 2 | $60.7M | 13 |
| KPRX | Kiora Pharmaceuticals | Ophthalmology Rare | 4 | Phase 3 | $4.1M | 4 |
| KURA | Kura Oncology | MetabolicOncology | 13 | Approved | $688M | 13 |
| KYMR | Kymera Therapeutics | DermatologyImmunology+1 Rare | 5 | Phase 2 | $10.4B | 5 |
| LBRX | LB Pharmaceuticals | Neurology | 3 | Phase 3 | $1.30B | 3 |
| LENZ | LENZ Therapeutics | Ophthalmology | 1 | Approved | $110M | 1 |
| LXEO | Lexeo Therapeutics | CardiovascularNeurology Rare | 1 | Phase 2 | $236M | 12 |
| LQDA | Liquidia | CardiovascularImmunology+1 Rare | 9 | Approved | $5.11B | 9 |
| MAIA | MAIA Biotechnology | Oncology | 8 | Phase 3 | $77.2M | 8 |
| MPLT | MapLight Therapeutics | Neurology | 3 | Phase 2 | $365M | 3 |
| MAZE | Maze Therapeutics | MetabolicRenal Rare | 4 | Phase 2 | $1.80B | 4 |
| MIST | Milestone Pharmaceuticals | Cardiovascular | 2 | Approved | $51.4M | 2 |
| MLYS | Mineralys Therapeutics | CardiovascularRenal+1 | 3 | NDA Submitted | $1.28B | 3 |
| MBRX | Moleculin Biotech | Oncology | 9 | Phase 2 | $7.3M | 9 |
| GLUE | Monte Rosa Therapeutics | CardiovascularDermatology+3 Rare | 7 | Phase 2 | $775M | 7 |
| NGEN | NervGen Pharma | Neurology | 1 | Phase 3 | $211M | 3 |
| NRSN | NeuroSense Therapeutics | Neurology Rare | 3 | Phase 2 | $2.9M | 3 |
| NAMS | NewAmsterdam Pharma | CardiovascularMetabolic+1 | 6 | NDA Submitted | $2.33B | 6 |
| NRXP | NRX Pharmaceuticals | Neurology Rare | 8 | Approved | $109M | 11 |
| NRIX | Nurix Therapeutics | ImmunologyNeurology+1 | 13 | Phase 3 | $1.56B | 13 |
| NVCT | Nuvectis Pharma | HematologyOncology+1 Rare | 9 | Phase 3 | $660M | 9 |
| OCS | Oculis Holding | NeurologyOphthalmology Rare | 3 | Phase 3 | $418M | 5 |
| OLMA | Olema Pharmaceuticals | Oncology | 3 | Phase 3 | $633M | 3 |
| OMER | Omeros | HematologyNeurology+2 Rare | 2 | Approved | $1.04B | 6 |
| OKUR | OnKure Therapeutics | Oncology | 2 | Preclinical | $104M | 2 |
| IRD | Opus Genetics | Ophthalmology Rare | 4 | Approved | $391M | 12 |
| ORIC | Oric Pharmaceuticals | Oncology | 5 | Phase 3 | $831M | 5 |
| OVID | Ovid Therapeutics | Neurology Rare | 4 | Phase 2 | $419M | 4 |
| PALI | Palisade Bio | Immunology | 2 | Phase 2 | $181M | 3 |
| KTTA | Pasithea Therapeutics | NeurologyOncology Rare | 4 | Phase 1 | $16.0M | 4 |
| PMVP | PMV Pharmaceuticals | Oncology | 7 | Phase 2 | $92.2M | 7 |
| PYPD | PolyPid | Infectious DiseaseMetabolic+1 | 3 | NDA Submitted | $138M | 4 |
| PRLD | Prelude Therapeutics | HematologyOncology Rare | 3 | Phase 1 | $266M | 3 |
| PCSA | Processa Pharmaceuticals | GI/HepatologyImmunology+2 Rare | 7 | Phase 2 | $4.8M | 7 |
| PTGX | Protagonist Therapeutics | DermatologyHematology+2 Rare | 1 | Approved | $8.14B | 12 |
| TARA | Protara Therapeutics | DermatologyMetabolic+1 Rare | 1 | Phase 3 | $143M | 3 |
| QNRX | Quoin Pharmaceuticals | DermatologyImmunology Rare | 4 | Phase 2 | $236M | 4 |
| RAPP | Rapport Therapeutics | Neurology | 6 | Phase 3 | $1.41B | 6 |
| RXRX | Recursion Pharmaceuticals | Oncology | 6 | Phase 2 | $1.69B | 6 |
| RLAY | Relay Therapeutics | DermatologyOncology Rare | 4 | Approved | $3.64B | 4 |
| RLMD | Relmada Therapeutics | MetabolicNeurology+1 Rare | 4 | Phase 2 | $321M | 4 |
| RVPH | Reviva Pharmaceuticals | CardiovascularDermatology+3 Rare | 11 | Phase 3 | $4.7M | 11 |
| RVMD | Revolution Medicines | Oncology | 11 | Approved | $35.2B | 11 |
| RYTM | Rhythm Pharmaceuticals | Metabolic Rare | 2 | Approved | $8.08B | 14 |
| SGMT | Sagimet Biosciences | DermatologyMetabolic | 3 | Phase 3 | $709M | 3 |
| SCYX | Scynexis | Infectious DiseaseRenal Rare | 5 | Approved | $28.4M | 5 |
| SLS | SELLAS Life Sciences Group | Oncology | 4 | Phase 3 | $3.90B | 9 |
| SEPN | Septerna | ImmunologyMetabolic+1 Rare | 5 | Phase 1 | $1.90B | 5 |
| SION | Sionna Therapeutics | Respiratory Rare | 5 | Phase 2 | $139M | 5 |
| GPCR | Structure Therapeutics | MetabolicRespiratory Rare | 5 | Phase 3 | $3.90B | 5 |
| SNDX | Syndax Pharmaceuticals | ImmunologyOncology Rare | 6 | Approved | $822M | 7 |
| TNGX | Tango Therapeutics | Oncology | 5 | Phase 1 | $3.75B | 5 |
| TLX | Telix Pharmaceuticals | Oncology | 14 | Approved | $3.01B | 25 |
| TENX | Tenax Therapeutics | Cardiovascular Rare | 2 | Phase 3 | $64.7M | 2 |
| TVTX | Travere Therapeutics | MetabolicRenal Rare | 6 | Approved | $4.91B | 7 |
| TTRX | Turn Therapeutics | DermatologyInfectious Disease Rare | 3 | Phase 2 | $261M | 4 |
| TYRA | Tyra Biosciences | MetabolicOncology Rare | 5 | Phase 2 | $1.35B | 5 |
| RARE | Ultragenyx Pharmaceutical | CardiovascularMetabolic+1 Rare | 2 | Approved | $1.70B | 10 |
| UNCY | Unicycive Therapeutics | Renal | 2 | NDA Submitted | $108M | 2 |
| VNDA | Vanda Pharmaceuticals | CardiovascularDermatology+6 Rare | 23 | Approved | $230M | 27 |
| VSTM | Verastem | Oncology | 5 | Approved | $934M | 5 |
| VRCA | Verrica Pharmaceuticals | DermatologyOncology Rare | 2 | Approved | $53.9M | 4 |
| VKTX | Viking Therapeutics | MetabolicNeurology Rare | 4 | Phase 3 | $3.43B | 9 |
| VYGR | Voyager Therapeutics | MetabolicNeurology Rare | 4 | Phase 1 | $94.6M | 9 |
| VTVT | vTv Therapeutics | HematologyMetabolic+1 Rare | 9 | Phase 3 | $69.4M | 9 |
| XFOR | X4 Pharmaceuticals | — | 2 | Approved | $316M | 2 |
| XENE | Xenon Pharmaceuticals | Neurology Rare | 9 | NDA Submitted | $3.81B | 9 |
| XERS | Xeris Biopharma | MetabolicNeurology Rare | 3 | Approved | $3.07B | 4 |
| ZBIO | Zenas BioPharma | DermatologyImmunology+2 Rare | 4 | NDA Submitted | $1.88B | 11 |
| ZNTL | Zentalis Pharmaceuticals | Oncology | 1 | Phase 3 | $146M | 1 |
| ZYME | Zymeworks | OncologyRespiratory | 1 | Approved | $1.78B | 12 |
No companies match.